Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Regulatory summary with limited context. A compound-specific science and safety review is still missing.
Prohibited at all times
1-Androsterone is covered by S1.1 of the effective 2026 WADA List and is prohibited in and out of competition. S1.1 applies to exogenous administration; its coverage is not limited to the named examples and includes relevant esters. [3]
S1.1; 2026 List, printed pages 5–6 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
List year
The 2026 List is the effective edition on this review date. The checked 2027 S1 text showed no change, but the 2027 edition does not take effect until 1 January 2027. [3] [4] [2]
- Consult the official edition and responsible anti-doping organization for consequential decisions. This reference does not provide medical advice, a TUE decision, product certification or individual clearance.
Identity caution
A historical product labeled 1-Androsterone was chemically identified as the 3-beta-hydroxy compound corresponding to 1-epiandrosterone. Its findings must not be assigned to this separate 3-alpha compound merely because the marketed name looks similar. [1]
- Marketing names alone are insufficient for chemical identification.
What remains uncertain
- Molecule-specific evidence was not sufficiently verified for a substantive public profile in this review. This is a rule-only entry, not a thorough molecule review; absence of reviewed evidence does not establish safety.
- Chemical registry identifiers, every alias and jurisdiction-specific product availability have not been exhaustively reconciled.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- Seized designer supplement named "1-Androsterone": identification as 3β-hydroxy-5α-androst-1-en-17-one and its urinary elimination. ↗Accessed 2026-11-10 · indexed original abstract read via Europe PMC MED record; full article not reviewed
Abstract; PMID 21310167
- 2027 Prohibited List resource page ↗Accessed 2026-11-10 · relevant primary-source text read · FUTURE 2027 SOURCE
Resource description and effective date
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · relevant primary-source text read
Introduction and S1, printed pages 3, 5–6
- WADA 2027 Prohibited List, currently linked English file ↗Accessed 2026-11-10 · relevant primary-source text read · FUTURE 2027 SOURCE
Cover and S1, printed pages 1, 5–6
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.